Sirtex Medical Introduces SIR-Spheres® FLEXdose SELECT Delivery Program for Selective Y-90 Treatments

Sirtex Medical has unveiled a new development in the treatment of metastatic colorectal cancer with the launch of the SIR-Spheres® FLEXdose SELECT Delivery Program. This innovative program introduces a 3mL vial configuration, allowing for more precise and tailored internal radiation therapy using Y-90 microspheres.

The SIR-Spheres® FLEXdose SELECT Delivery Program is designed to provide unparalleled flexibility in patient-specific dosing from a single 3mL vial. The new vials contain approximately 27 million microspheres, compared to the current 5mL vials which contain about 44 million microspheres. This reduced volume facilitates a more selective treatment approach, with pre-calibration available every day of the week. The program aims to improve the targeting of Y-90 delivery, offering more precise treatment options.

Matt Schmidt, CEO of Sirtex Medical Limited, expressed enthusiasm about the new program, highlighting that it represents the company's commitment to responding to the needs of both patients and physicians. He emphasized that the SIR-Spheres® FLEXdose SELECT Delivery Program will enable access to personalized Y-90 resin doses, which can expedite treatment for patients.

Dr. Ripal Gandhi from the Miami Cardiac & Vascular Institute and Miami Cancer Institute praised the new program. He noted that the SIR-Spheres® FLEXdose Program has been instrumental in providing timely treatments for his patients. With the flexibility of daily availability, Dr. Gandhi can personalize the Y-90 treatments for each patient, optimizing treatment strategies.

The introduction of the 3mL SIR-Spheres® Y-90 resin microspheres vials marks a significant advancement in the field of radioembolization therapy. These vials are now available for order, indicating a step forward in delivering more efficient and patient-specific treatments.

SIR-Spheres® are used in selective internal radiation therapy (SIRT) and are specifically indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer. SIRT involves delivering radiation directly to the liver tumors via the intra-hepatic artery. The SIR-Spheres® device is regulated under Federal (USA) law and requires a physician's prescription. Detailed instructions, including indications, contraindications, side effects, warnings, and precautions, are provided with the device to ensure proper usage.

Sirtex Medical, with offices in the U.S., Australia, Europe, and Asia, continues to advance its mission to improve cancer treatment outcomes. Its leading product, the SIR-Spheres® Y-90 resin microspheres, is a targeted radiation therapy for liver cancer. This latest innovation aligns with Sirtex's ongoing efforts to enhance treatment options and outcomes for patients with cancer, reflecting the company's dedication to innovation in the healthcare sector.

The SIR-Spheres® FLEXdose SELECT Delivery Program represents a significant breakthrough in offering more tailored and effective treatment options for patients with metastatic colorectal cancer. By introducing a more flexible dosing system, Sirtex Medical is addressing the need for more personalized and timely treatment solutions, ultimately aiming to improve patient outcomes in the battle against cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!